Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Lymphoma Clinical Trial

Official title:

An i3+3 Phase I Dose-per-Fraction Escalation Trial for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05019976
• Other study ID #: IRB21-0666
• Status: Recruiting
• Phase: N/A
• Start date: September 30, 2021
• Est. completion date: December 1, 2027

Study information

• Verified date: January 2024
• Source: University of Chicago
• Contact: Yasmin Hasan, MD
• Phone: (773) 702-2856
• Email: yhasan[@]radonc.uchicago.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study focuses on using shortened courses of radiation for participants with relapsed/refractory Hodgkin/Non-Hodgkin lymphoma. Treatment radiation over 5-6 weeks is often standard of care for many people with lymphoma, but doctors leading this study aim to find out if using radiation for a shorter period of time can be safe for treating lymphoma and if so, what is the safest shortened dose of radiation for participants.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 1, 2027
• Est. primary completion date: December 1, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

INCLUSION CRITERIA:

1. Signed Written Informed Consent:

• Participants must be able to give self-consent and then sign and date an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent in accordance with local regulatory and institutional guidelines. This consent must be obtained before the performance of any protocol-related procedures that are not considered part of normal participant care.

• Participants must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study.

2. Must have the following disease/participant characteristics:

• Men or women = 18 years of age.

• Must have clinically confirmed relapsed/refractory Hodgkin/non-Hodgkin lymphoma

• Mush have undergone appropriate standard of care treatment options (in the opinion of the treating investigator).

• Must have measurable disease/tumors as defined by RECIST Version 1.1, including at least one tumor lesion that meets criteria for radiation (0.25 cc to 65 cc of viable tumor approximately 5 cm in maximal dimension). Tumors larger than 65 cc can be partially treated but the whole tumor should receive at least the minimal prescribed dose.

• Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of = 2

• Must have adequate organ function, as defined by clinical lab values provided to the study doctor.

• Must have an doctor-determined life expectancy of at least 1 month.

• Participants who are women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 72 hours prior to the start of study.

• Participants who are women must not be breastfeeding.

• Participants who are WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) and up to 5 months post last dose of study drug(s).

• Participants who are WOCBP who are continuously not heterosexually active are exempted from contraceptive requirements but still must undergo pregnancy testing as described in this section.

• Participants who are males and who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) and up to 7 months post last dose of study drug(s). In addition, male participants must be willing to refrain from sperm donation during this time.

• Participants who are azoospermic males (males who dont ejaculate without sperm) are exempt from contraceptive requirements.

• Study doctors shall counsel WOCBP, and male participants who are sexually active with WOCBP, on the importance of pregnancy prevention and the implications of an unexpected pregnancy. Investigators shall advise on the use of highly effective methods of contraception, which have a failure rate of < 1% when used consistently and correctly.

EXCLUSION CRITERIA:

• Participants must not have an indolent lymphoma or other type of lymphoma which could be effectively treated with radiation doses substantially less then and EQD2 of 50 Gy

• Participants must not receive concurrent chemotherapy, targeted small molecule therapy, radiation or other anti-cancer therapy (with exceptions for disease-specific hormone treatments considered standard of care), anti-cancer monoclonal antibody (mAb) or have not recovered (i.e. < grade 1 or at baseline) from adverse events due to a previously administered agent. Participants may receive concurrent steroids.

i) Note: subjects with < grade 2 neuropathy are an exception to this criterion and may qualify for the study.

ii) Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

iii) Note: subjects with any grade alopecia are an exception to this criterion and may qualify for the study

• Participants must not have had prior radiation therapy (defined as >10% of prior prescription dose) to the area planning to be treated with radiation.

• Participants who have had prior cytotoxic chemotherapy must not receive that therapy within 2 weeks of the initiation of radiation

• Participants who have had prior anti-cancer monoclonal antibody (mAb) or other small molecules must not receive that therapy within 7 days of the initiation of radiation

• Participants must not have a known additional malignancy that could confuse analysis of on-study treatment. Inclusion of all study participants with more than one malignancy must be discussed and approved by the PI.

• Participants must not have a known history of non-infectious pneumonitis that required steroids for treatment.

• Participants must not have evidence of interstitial lung disease.

• Participants must not have a current seizure disorder.

• Participants must not have a history or current evidence of any condition, therapy or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

• Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.

• If known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected) then patient is not eligible for treatment of liver lesions

• Participants must not have had uncontrolled or significant cardiovascular disease including, but not limited to, any of the following:

• Myocardial infarction or stroke/transient ischemic attack within the past 6 months

• Uncontrolled angina within the past 3 months

• Any history of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes)

• History of other clinically significant heart disease (e.g. cardiomyopathy, congestive heart failure with New York Heart Association functional classification III to IV, pericarditis, significant pericardial effusion, or myocarditis)

• Cardiovascular disease-related requirement for daily supplemental oxygen therapy.

• Participants may not concomitantly use statins while on study. However, a patient using statins for over 3 months prior to study drug administration and in stable status without CK rise may be permitted to enroll.

• Participants may not have current or history of clinically significant muscle disorders (e.g. myositis), recent unresolved muscle injury, or any condition known to elevate serum CK levels.

• Participants must not be prisoners or be involuntarily incarcerated.

• Participants must not be compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.

Related Conditions & MeSH terms

• Hodgkin Lymphoma
• Lymphoma
• Lymphoma, Non-Hodgkin
• Non-hodgkin Lymphoma

Intervention

Radiation:
• Radiation - Dose Level 0
Dose Per Fraction (Each Radiation Treatment): 3.2Gy to 2.4Gy (minimal dose) depending on what study doctor prescribes Total Dose of Radiation for Treatment Period: 44.8Gy to 33.6Gy (minimal dose) depending on what study doctor prescribes Total Number of Radiation Treatments: 14
• Radiation - Dose Level 1
Dose Per Fraction (Each Radiation Treatment): 4.2Gy to 3.2Gy (minimal dose) depending on what study doctor prescribes Total Dose of Radiation for Treatment Period: 42Gy to 32Gy (minimal dose) depending on what study doctor prescribes Total Number of Radiation Treatments: 10
• Radiation - Dose Level 2
Dose Per Fraction (Each Radiation Treatment): 5.2Gy to 4.2Gy (minimal dose) depending on what study doctor prescribes Total Dose of Radiation for Treatment Period: 39.2Gy to 29.4Gy (minimal dose) depending on what study doctor prescribes Total Number of Radiation Treatments: 7
• Radiation - Dose Level 3
Dose Per Fraction (Each Radiation Treatment): 6.8Gy to 5.4Gy (minimal dose) depending on what study doctor prescribes Total Dose of Radiation for Treatment Period: 34Gy to 27Gy (minimal dose) depending on what study doctor prescribes Total Number of Radiation Treatments: 5
• Radiation - Dose Level 4
Dose Per Fraction (Each Radiation Treatment): 10Gy to 7.8Gy (minimal dose) depending on what study doctor prescribes Total Dose of Radiation for Treatment Period: 30Gy to 23.4Gy (minimal dose) depending on what study doctor prescribes Total Number of Radiation Treatments: 3

Locations

Country	Name	City	State
United States	University of Chicago	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose Per Fraction of Radiation	Maximum tolerated dose of radiation per fraction among participants with relapsed/refractory Hodgkin/non-Hodgkin lymphoma as assessed by dose-limiting toxicities (severe side effects that limit the dose of radiation) defined by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.	1 Month
Secondary	Rate of Reported Adverse Events Within 1 Month of Radiation	The rate of reported adverse events (side effects) within 1 month of starting radiation as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.	1 Month
Secondary	Rate of Long-Term Adverse Events (Up to 2 Years) From the End of Radiation Rate of Long-Term Adverse Events (Up to 2 Years) From the End of Radiation	The rates of reported long-term adverse events from the end of radiation up to a maximum of 2 years as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.	Up to 2 years after last dose of radiation
Secondary	Overall Response Rate to Radiation Treatment	Overall response rate to radiation (including irradiated and non-irradiated lesions) as assessed by computed tomography scans of lesions based on tumor measurements according to Response Evaluation Criteria in Solid Tumors (RECIST criteria Version 1.1 ).	Up to 2 years after last dose of radiation
Secondary	Progression-Free Survival of Participants After Radiation Treatment	Progression-free survival after radiation as assessed by computed tomography (CT) scans of lesions, tumor measurements according to Response Evaluation Criteria in Solid Tumors and clinical records.	Up to 2 years after last dose of radiation
Secondary	Overall Survival After Radiation Treatment	Overall survival after radiation as assessed by computed tomography (CT) scans of lesions, tumor measurements according to Response Evaluation Criteria in Solid Tumors(RECIST Version 1.1) and clinical records.	Up to 2 years after last dose of radiation
Secondary	Local Control of Treated Lesions After Radiation Treatment	Local control of the treated lesion as assessed by computed tomography (CT) scans of lesions, tumor measurements according to Response Evaluation Criteria in Solid Tumors (RECIST criteria Version 1.1 ) and clinical records.	Up to 2 years after last dose of radiation